Evidence Hub

Evaluation of GFAP and phosphorylated tau correlation in human blood using magnetic bead‐based electrochemical sensor

Hana Cho, Kyoung-Ryul Lee, Seongeun Jeong, Sang-Heon Park, Soo Hyun Lee

Alzheimer's & Dementia, 2025

Abstract

Abstract Background Blood biomarkers are regarded as a method for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD). Amyloid‐beta (Aβ) and phosphorylated tau (p‐tau) are widely used blood biomarkers; nonetheless, it is essential to explore additional promising candidates for the validation of pathological mechanisms and the reliability of clinical data. Glial fibrillary acidic protein (GFAP) has the potential to reflect and predict worsening disability in individuals with degenerative diseases. We aimed to measure GFAP and p‐tau levels in human blood and evaluate the correlation. Method Magnetic beads were coated with a primary antibody that was specifically bound to the antigen. For the GFAP tests, beads were incubated with 3 groups from: 1) normal control (NC, n = 5), 2) mild cognitive impairment (MCI, n = 5), and 3) Alzheimer's disease (AD, n = 5). For p‐tau levels measurement, all samples were bound to secondary antibodies such as O‐glycosylated tau (O‐g tau) and p‐tau. We compare GFAP and p‐tau impedance change rates to diagnose NC/MCI/AD and discuss the correlation between the two AD biomarkers. Result In the NC group, both GFAP and p‐tau exhibited low rates of impedance change. Patients with MCI showed a slightly high rate of impedance change compared to the NC. We established a cut‐off value to enhance the diagnostic reliability of NC and MCI. The AD patient exhibited the highest rate of impedance change, about double that of NC. The enhanced…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free